ClinicalTrials.gg
Sign In
Drug

Sorafenib clinical trials

Also written Nexavar, BAY 43-9006 and BAY 54-9085.

studies test it
485
open now
11
in phase 3
48
first study started
2002

How each study uses Sorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Sorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Dec 2005 · NEXAVAR · NDA 021923 (FDA, Drugs@FDA)
European Union
19 Jul 2006 · Nexavar · EMEA/H/C/000690 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sorafenib
260
sorafenib tosylate
127
SFN
48
BAY 43-9006 Tosylate Salt
44
BAY 43-9006 Tosylate
33

Brand

Nexavar
204

Development codes

BAY 43-9006
103
BAY 54-9085
79
NSC 724772
3

In one entry with another drug

Given together, or one or the other

Sorafenib + Pravastatin
2

Studies by the year they started

484 studies that test it; most in 2007 (74)

Studies that test Sorafenib, by start year
YearStudies
20024
20031
200424
200545
200636
200774
200866
200957
201030
201132
201223
201317
201413
201515
201611
20179
20184
20194
20204
20213
20224
20231
20243
20253
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
170
Phase 2
301
Phase 3
48
Phase 4
4
No phase
18

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Hepatocellular
96
Carcinoma, Renal Cell
50
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
23
Melanoma
17
Leukemia, Myeloid, Acute
17
Neoplasms
15
Pancreatic Neoplasms
12
Prostatic Neoplasms
11
Liver Neoplasms
10
Glioblastoma
8
Sarcoma
8

Who runs them

Industry 69 · Other 416

National Cancer Institute (NCI) (74) · Bayer (47) · M.D. Anderson Cancer Center (21) · Memorial Sloan Kettering Cancer Center (8) · SCRI Development Innovations, LLC (8) · University Health Network, Toronto (8) · St. Jude Children's Research Hospital (7) · H. Lee Moffitt Cancer Center and Research Institute (6)

Often tested with

Tested in the same studies.

Bevacizumab (19) · Cisplatin (18) · Gemcitabine (16) · Paclitaxel (13) · Everolimus (13) · Erlotinib (13) · Carboplatin (12) · Capecitabine (11)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 6 phase 3 studies under way

Sorafenib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 10, 2 in phase 3

Studies that test Sorafenib, phase 3 first.

Studies

Open first, then newest update. How each study uses Sorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 485

See all 485 studies that test Sorafenib →

Given beside what is tested · 103 — Sorafenib is usual care or a partner of the new treatment

Showing 20 of 103.

As the comparator · 56 — what is tested is compared with Sorafenib

Showing 20 of 56.

What changed recently

From the registry's own updates since Oct 15, 2026.

Results posted2

Stopped1

Codes

What other systems call Sorafenib · ClinicalTrials.gg INT006656

  • MeSH (NLM) D000077157SorafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 9ZOQ3TZI87SORAFENIBConfirmed FDA, NLM, Wikidata
  • RxNorm 495881Confirmed FDA, Wikidata
  • Wikidata Q421136sorafenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61948SorafenibOne source FDA
  • DrugBank DB00398One source Wikidata

Also registered as bay-673472 (UNII 5XYK65KIGD) and sorafenib tosylate (UNII 5T62Q3B36J · RxNorm 597744).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.